Testimony Before the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Regarding Flibanserin

View as PDF.

Public Citizen strongly opposes Food and Drug Administration (FDA) approval of the new drug application for flibanserin for treatment of hypoactive sexual desire disorder in premenopausal women. The FDA previously rejected approval of the drug in 2010 and 2013. There is now considerably more evidence that the drug’s risks outweigh its benefits.